MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Gross Profit 2011-2026 | NEOG
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 421 M | 464 M | 406 M | 243 M | 215 M | 196 M | 192 M | 190 M | 172 M | 153 M | 140 M | 123 M | 109 M | 92.4 M | 87.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 464 M | 87.8 M | 214 M |
Quarterly Gross Profit Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 95 M | - | 110 M | 113 M | 105 M | - | 117 M | 117 M | 117 M | - | 108 M | 113 M | 62.3 M | 175 M | 57.4 M | 60.6 M | 60 M | 121 M | 53.8 M | 53.2 M | 50.3 M | 53.2 M | 45.3 M | 51 M | 48.2 M | 51 M | 48.2 M | 50 M | 46.7 M | 50 M | 46.7 M | 48.2 M | 44.9 M | 49.3 M | 45.9 M | 43.6 M | 40.5 M | 43.6 M | 40.5 M | 38.2 M | 37.8 M | 38.2 M | 37.8 M | 34.2 M | 34.1 M | 34.2 M | 34.1 M | 29.5 M | 30.4 M | 29.5 M | 30.4 M | 27.3 M | 26.5 M | 27.3 M | 26.5 M | 22.7 M | 23 M | 22.7 M | 23 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 175 M | 22.7 M | 57 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
388 M | $ 9.0 | 1.47 % | $ 600 M | USA |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 13.99 | 2.49 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
53 M | $ 26.24 | 1.59 % | $ 729 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
958 M | $ 154.17 | 1.45 % | $ 7.64 B | USA |
 |
DexCom
DXCM
|
2.8 B | $ 68.54 | 3.32 % | $ 26.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 17.77 | 2.6 % | $ 947 M | USA |
 |
Guardant Health
GH
|
144 M | $ 88.16 | 1.12 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
2.26 B | $ 103.95 | 0.1 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
107 M | $ 15.57 | 4.15 % | $ 471 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
18.5 M | $ 17.22 | -0.4 % | $ 2.23 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 101.08 | 3.55 % | $ 8.34 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
83.8 K | $ 2.88 | 1.23 % | $ 93.5 K | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 169.85 | 3.01 % | $ 29.2 B | USA |
 |
Danaher Corporation
DHR
|
14.5 B | $ 195.65 | 2.23 % | $ 139 B | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.86 B | $ 121.72 | 2.04 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 198.39 | -0.28 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
2.84 B | $ 113.9 | 1.85 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.12 | 0.91 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 9.28 | 10.24 % | $ 263 M | Israel |
 |
NeoGenomics
NEO
|
314 M | $ 8.39 | 1.76 % | $ 1.07 B | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 78.83 | 0.41 % | $ 5.32 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.41 | 3.68 % | $ 423 M | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
246 M | $ 458.61 | 1.1 % | $ 13.2 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 220.43 | 1.77 % | $ 25.2 B |  Schweiz |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 18.31 | 5.23 % | $ 410 M | USA |
 |
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
127 M | $ 201.15 | 1.76 % | $ 19.8 B | USA |
 |
OPKO Health
OPK
|
219 M | $ 1.2 | 0.84 % | $ 833 M | USA |